This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use

 
 

02Nov

2017 BioInfect Conference

Location: Alderley Park Conference Centre, Cheshire


A major 1-day conference looking at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance.

Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections they cause ineffective. When the microorganisms become resistant to most antimicrobials they are often referred to as “superbugs”. This is a major concern because a resistant infection may kill, can spread to others, and imposes huge costs to individuals and society.

Antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. It is an increasingly serious threat to global public health that requires action across all government sectors and society.

Conference Programme

Time

Session

Speakers

08.30-09.00

Coffee & Registration

09.00-09.10

Welcome to the Conference

Geoff Davison, Chief Executive Officer, Bionow

09.10-09.40

Keynote Address

Tyler Merkeley, CARB-X Program Manager, BARDA

09.40-10.55

State of the AMR Nation

Session Chair: Jo Pisani, Pharmaceutical and Life Science Consulting Leader, PwC
Panelists
Tyler Merkeley, CARB-X Program Manager, BARDA
Pete Jackson, Executive Director, AMR Centre
John Fitzgerald, Secretary General, RUMA
Jonathan O'Halloran, Chief Scientific Officer, QuantuMDx
Richard Seabrook, Senior Advisor - AMR Lead, Medicines Discovery Catapult

10.55-11.35

Coffee, Networking & Exhibiton

11.35-12.35

Making Progress - Active Programmes to Advance the Antibiotic Pipeline: Part 1

Peter Warn, Senior Vice President Anti-Infective Discovery, Evotec / Forge Therapeutics
Jean de Gunzberg, Chief Scientific Officer, Da Volterra
Giancarlo Biagini, Professor, Liverpool School of Tropical Medicine

12.35-13.05

Antibacterial Drug R&D Strategies: Medical Need and Public Support

Ursula Theuretzbacher, Founder & Principal, Centre for Anti-Infective Agents 

13.05-14.20

Lunch, Networking & Exhibition

 

14.20-15.35

Making Progress - Active programmes to Advance the Antibiotic Pipeline: Part 2

Glenn Dale, Head of Early Development Antimicrobials, Polyphor
Emma Leire, Microbiology Team Lead, Centauri Therapeutics
Paul Ko Ferrigno, CEO, MetaLinear
Irina Barbolina, Senior Biologist & Laboratory Manager, LIG Biowise

15.35-16.35

Funding and Building Partnerships

Session Chair: Pete Jackson, AMR Centre
Gabriela Juarez-Martinez, UK China Partnership
Claire Thompson, Royal Pharmaceutical Society
Shampa Das, Molecular and Clinical Pharmacology, University of Liverpool
Colin Garner, Chief Executive, Antibiotics Research UK

16.35

Closing Remarks


Delegate Fees*
Premium Member: £150.00 + VAT
Member: £175.00 + VAT
Non-Member: £275.00 + VAT

To discuss the sponsorship and exhibition opportunities at the conference, please contact Helen Williams at helen.williams@bionow.co.uk or on 07714 168020.

> Register here